{
    "clinical_study": {
        "@rank": "168300", 
        "arm_group": [
            {
                "arm_group_label": "Teneli (Teneligliptin) /Teneli + insulin", 
                "arm_group_type": "Experimental", 
                "description": "Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin."
            }, 
            {
                "arm_group_label": "Placebo/Teneli (Teneligliptin) + insulin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in\n      combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to\n      evaluate the safety and efficacy of Teneligliptin in combination with Insulin with an\n      extension treatment for up to 52 weeks."
        }, 
        "brief_title": "Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who has been receiving a stable dose and regimen of insulin over 12 weeks\n             before administration of investigational drug\n\n          -  Patients who are under dietary management and taking therapeutic exercise for\n             diabetes over 12 weeks before administration of investigational drug\n\n          -  Patients whose HbA1c is between 7.5% and 10.5%\n\n          -  Patients who were not administered diabetes therapeutic drugs prohibited for\n             concomitant use within 12 weeks before administration of investigational drug.\n\n        Exclusion Criteria:\n\n          -  Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or\n             secondary diabetes (Cushing disease, acromegaly, etc)\n\n          -  Patients who are accepting treatments of arrhythmias\n\n          -  Patients with serious diabetic complications\n\n          -  Patients who are the excessive alcohol addicts\n\n          -  Patients with severe hepatic disorder or severe renal disorder.\n\n          -  Patients who are pregnant, lactating, and probably pregnant patients, and patients\n             who can not agree to contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081599", 
            "org_study_id": "3000-A15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Teneli (Teneligliptin) /Teneli + insulin", 
                "description": "Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.", 
                "intervention_name": "Teneli (Teneligliptin) /Teneli", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo/Teneli (Teneligliptin) + insulin", 
                "description": "Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.", 
                "intervention_name": "Placebo/Teneli (Teneligliptin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Teneli (Teneligliptin) /Teneli + insulin", 
                    "Placebo/Teneli (Teneligliptin) + insulin"
                ], 
                "description": "Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.", 
                "intervention_name": "Insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "insulin resistance", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chuo-ku", 
                    "country": "Japan", 
                    "state": "Tokyo"
                }, 
                "name": "Investigational site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IV Study of Teneligliptin (MP-513) in Combination With Insulin in Japanese Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": [
            {
                "affiliation": "Tokyo University", 
                "last_name": "Takashi Kadowaki, Professor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Mitsubishi Tanabe Pharma Corporation", 
                "last_name": "Kazuoki Kondo, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.", 
            "measure": "Change from Baseline in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "at Week 0 and Week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change from Baseline in Fasting Plasma Glucose collected at Week 16. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate.", 
                "measure": "Change from Baseline in Fasting Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "at Week 0 and Week 16"
            }, 
            {
                "description": "The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 16. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate.", 
                "measure": "Change from Baseline in the Areas Under the Curve from 0 to 2 h (AUC0-2h)  for Postprandial Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2 hours post-dose at Week 0 and Week 16"
            }, 
            {
                "description": "The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 16. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate.", 
                "measure": "Change from baseline in 2-hour Postprandial Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "at Week 0 and Week 16"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}